Paper Review Records
All Paper Review Records
21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
97
days
Astragaloside IV ameliorates cognitive impairment after traumatic brain injury with involvement of NMDAR-related signaling
Authors
Chenglang Jiang; Weiqi Shen; Xin Liu; Yuhang Hui; Boru HouShow moreShow less
Affiliations
1. The Second Hospital & Clinical Medical School, Lanzhou University , Lanzhou , Gansu , China; 2. Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University , Lanzhou , Gansu , China; 3. Academician Workstation of the Second Hospital & Clinical Medical School, Lanzhou University , Lanzhou , Gansu , ChinaShow moreShow less
22
days
Disitamab vedotin combined with PD-1 inhibitors for postoperative adjuvant therapy in upper tract urothelial carcinoma: a retrospective exploratory case series
Authors
Yongbao Wei; Huaishan Hong; Dewen Zhong; Ruochen Zhang; Zhixuan Guo; Huang Lin; Jun Lin; Tao Li; Jinfeng Wu; Jianhui Chen; Yi ZhangShow moreShow less
Affiliations
1. Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, China; 2. Department of Urology, Longyan First Affiliated Hospital of Fujian Medical University, China; 3. Department of Urology, Fujian Medical University Union Hospital, China; 4. Department of Urology, The Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine, ChinaShow moreShow less
26
days
Rare disease clinical trials in Italy (2022–May 2026): current trends, future challenges, and the evolving role as reporting member state
Authors
Eleonora De Paola; Fabrizio Galliccia; Raffaella Maione; Natalia Maria Verrelli; Diego Alejandro DriShow moreShow less
Affiliations
1. Clinical Trials Office, Italian Medicines Agency (AIFA), Italy; 2. Department of Pharmacy, School of Specialisation in Hospital Pharmacy, University of Pisa, ItalyShow moreShow less
48
days
Hormophysa cuneiformis protects against methamphetamine-induced hepatotoxicity via antioxidant, anti-inflammatory, and autophagy-regulatory mechanisms: histological and biochemical studies
Authors
Mayada Elhusseiny; Rabab S. El-Kelany; Rania A. El-Shenody; Mohamed S. El-Hashash; Mostafa E. Elshobary; Samar Sami AlkafaasShow moreShow less
Affiliations
1. Histology and Cell Biology Department, Faculty of Medicine, Tanta University, Egypt; 2. Forensic Medicine and Clinical Toxicology at the Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Tanta University, Egypt; 3. Botany and Microbiology Department, Faculty of Science, Tanta University, Egypt; 4. Aquaculture Research, AWI-Helmholtz Centre for Polar and Marine Research, Germany; 5. Molecular Cell Biology Unit, Division of Biochemistry, Department of Chemistry, Faculty of Science, Tanta University, EgyptShow moreShow less
50
days
Anti-tumor activity of valproic acid in EBV-positive Burkitt lymphoma via PFN2-associated PI3K/AKT pathway repression
Authors
Yongliang Zheng; Yuxiu Yang; Shouhua Zhang; Rui Liu; Zujie Lin; Yuanqiao He; Yaoling Luo; Aili HeShow moreShow less
Affiliations
1. Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, China; 2. Department of Hematology, The Affiliated Hospital of Jinggangshan University, China; 3. School of Pharmacy, Jiangxi Science and Technology Normal University, China; 4. Department of General Surgery, Jiangxi Provincial Children’s Hospital, The Affiliated Children’s Hospital of Nanchang Medical College, China; 5. Center of Laboratory Animal Science, Nanchang University, China; 6. Key Laboratory of New Drug Evaluation and Transformation of Jiangxi Province, China; 7. Clinical Medicine Research Center, First Affiliated Hospital of Gannan Medical University, China; 8. National-Local Joint Engineering Research Center of Biodiagnostics & Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University, China; 9. Department of Tumor and Immunology, Precision Medical Institute, Xi’an Jiaotong University, China; 10. Xi’an Key Laboratory of Hematological Diseases, ChinaShow moreShow less
58
days
Male sexual dysfunction associated with TNF-α inhibitors: an indication-stratified global pharmacovigilance analysis
Authors
Yi Chu; Min Luo; Wenyu Li; Xuehong Wang; Yuqian ZhouShow moreShow less
Affiliations
1. Department of Gastroenterology, The Second Xiangya Hospital of Central South University, ChinaShow moreShow less
FAQ
How long does Frontiers in Pharmacology take to review a manuscript?
As of 2026-11-19, CrushSCI has 21 complete review records for Frontiers in Pharmacology. The fastest paper went from submission to acceptance in 17 days (Bioresponsive gelatin-coated silk fibroin nanoparticles enhance roxadustat therapy in experimental pulmonary fibrosis, received 2026-06-28, accepted 2026-07-15); the slowest took 207 days. The average is 79.7 days and the median is 64 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
